NASDAQ:XBIT - XBiotech Stock Price, Forecast & News

XBiotech trades on the NASDAQ under the ticker symbol "XBIT."

XBiotech Inc (NASDAQ:XBIT) announced its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.15) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.15). View XBiotech's Earnings History.

XBiotech is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for XBiotech.

1 brokerages have issued 1-year price objectives for XBiotech's stock. Their forecasts range from $28.00 to $28.00. On average, they expect XBiotech's stock price to reach $28.00 in the next twelve months. This suggests a possible upside of 121.9% from the stock's current price. View Analyst Price Targets for XBiotech.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XBiotech in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for XBiotech.

Media coverage about XBIT stock has been trending somewhat positive on Thursday, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. XBiotech earned a news impact score of 0.7 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for XBiotech.

XBiotech saw a increase in short interest in the month of February. As of February 14th, there was short interest totalling 4,820,000 shares, an increase of 28.2% from the January 30th total of 3,760,000 shares. Based on an average daily volume of 735,000 shares, the short-interest ratio is currently 6.6 days. Approximately 26.4% of the company's stock are sold short. View XBiotech's Current Options Chain.

Some companies that are related to XBiotech include Aurinia Pharmaceuticals (AUPH), Cambrex (CBM), Prestige Consumer Healthcare (PBH), Pacira Biosciences (PCRX), Karuna Therapeutics (KRTX), Epizyme (EPZM), Xencor (XNCR), Turning Point Therapeutics (TPTX), Eidos Therapeutics (EIDX), Ironwood Pharmaceuticals (IRWD), Ligand Pharmaceuticals (LGND), Heron Therapeutics (HRTX), BELLUS Health (BLUSF), Tricida (TCDA) and Arvinas (ARVN).

Based on aggregate information from My MarketBeat watchlists, some companies that other XBiotech investors own include Zynerba Pharmaceuticals (ZYNE), TransEnterix (TRXC), Advanced Micro Devices (AMD), Amicus Therapeutics (FOLD), ImmunoGen (IMGN), TherapeuticsMD (TXMD), Ardelyx (ARDX), CymaBay Therapeutics (CBAY), Fate Therapeutics (FATE) and Gilead Sciences (GILD).

(XBIT) raised $76 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO.

XBiotech's stock is owned by many different of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.82%), State Street Corp (0.82%), Sofinnova Investments Inc. (0.59%), Bank of New York Mellon Corp (0.16%), Russell Investments Group Ltd. (0.14%) and Charles Schwab Investment Management Inc. (0.12%). Company insiders that own XBiotech stock include Fondation Rennes, Queena Han, W Thorpe Mckenzie and W Thorpe Mckenzie. View Institutional Ownership Trends for XBiotech.

XBIT stock was sold by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., EAM Investors LLC, State Street Corp, Strs Ohio, New York State Common Retirement Fund and Bank of America Corp DE. View Insider Buying and Selling for XBiotech.

XBIT stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., California Public Employees Retirement System, Geode Capital Management LLC, Silverleafe Capital Partners LLC, Virtus ETF Advisers LLC, UBS Group AG, Trexquant Investment LP and Caxton Associates LP. Company insiders that have bought XBiotech stock in the last two years include Fondation Rennes and W Thorpe Mckenzie. View Insider Buying and Selling for XBiotech.

Shares of XBIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of XBIT stock can currently be purchased for approximately $12.62.

XBiotech has a market capitalization of $518.56 million. The biopharmaceutical company earns $-21,140,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. XBiotech employs 56 workers across the globe.View Additional Information About XBiotech.

The official website for XBiotech is http://www.xbiotech.com/.

XBiotech's mailing address is 5217 Winnebago Ln, AUSTIN TX, 78744. The biopharmaceutical company can be reached via phone at 512-386-2900 or via email at [email protected]